Prospective, randomized, double-blind clinical trial about efficacy of homeopathic treatment in children with obstructive adenoid

AIM: the efficacy and security of homeopathic treatment was investigated on children with obstructive adenoid justifying an operation. STUDY DESIGN: Clinical prospective. MATERIAL AND METHOD: In a prospective, randomized, double-blind clinical trial included 40 children between the ages of 3 to 7 years old, 20 children were treated with homeopathic medication, based in the principle of similarity (Simillimum), and 20 children with placebo. All the children of the homeopathic group/ adenoid, were treated daily with Agraphis nutans 6 CH, Thuya 6 CH and Adenoid 21CH, and the patients of the placebo group received daily placebo medication. The duration of the study of each children was 4 months. The evaluation of the results was clinical, and it was made by questionnaire standard, clinical examination and direct flexible fiberoptic nasopharyngoscopy, in the first and last day of treatment. The criterion of selection was the adenoid that occuped more than 70% of the coanal space. RESULTS: From the group of 20 children treated with homeopathic treatment, 13 did not show any change on the size of adenoid after nasopharyngoscopy, and 7 children had their adenoid decreased; from another group of 20 children that have treated with placebo for 4 months, 11 did not show any change on the size of their adenoid, 4 had their adenoid decreased and 5 had their adenoid increased. The statistical analysis showed a not significant difference (P= 0,069). The clinical evaluation of the patients showed that from the group of 20 patients treated with homeopathy, 17 kept unchanging, with oral breathing and snoring, one patient got better, eliminating the snoring and two were cured, which mean that their oral breathing turned to nasal breathing without snoring. From the group of 20 patients treated with placebo, 17 kept unchanging, one eliminated the snoring and two were cured; and these differences were not statistically significant (P> 0,999). CONCLUSIONS: the homeopathic treatment was not efficient in the patients with obstructive adenoid, remaining it surgical indication in 85% of the children. The homeopathic remedies did not provoke adverse events in the children.OBJETIVO: Avaliar a eficácia e segurança do tratamento homeopático em crianças com adenóide obstrutiva, com indicação cirúrgica. FORMA DE ESTUDO: Clínico prospectivo. Material e método: Estudo prospectivo, duplo-cego, randomizado, em que foram incluídas 40 crianças com idade variando de 3 a 7 anos, 20 crianças foram tratadas com medicação homeopática individualizada (Simillimum), baseada no princípio da similitude e 20 crianças receberam placebo. Todas as crianças do grupo medicação homeopática foram medicadas diariamente com Agraphis nutans 6 CH, Thuya 6 CH e Adenóide 21CH; e as do grupo placebo receberam diariamente medicamentos sem o princípio ativo. A duração do estudo de cada paciente foi de 4 meses. A avaliação dos resultados foi clínica, por meio de questionário padrão, de exame otorrinolaringológico e nasofaringoscopia direta com fibroscópio flexível, no primeiro e no último dia de tratamento. Utilizou-se como critério de inclusão a adenóide que ocupou mais do que 70% da luz coanal. RESULTADOS: Das 20 crianças tratadas com medicamento homeopático, 13 não apresentaram alteração no tamanho da adenóide nos exames nasofaringoscópicos e 7 tiveram diminuição da adenóide; das 20 crianças que receberam placebo por 4 meses, 11 não apresentaram alterações no tamanho da adenóide, 4 tiveram diminuição da adenóide e 5 crianças tiveram aumento. Não houve diferença estatística significante entre os grupos (P= 0,069). Na avaliação clínica da evolução dos pacientes, dos 20 pacientes tratados com medicamento homeopático, 17 se mantiveram inalterados, com respiração oral e ronco, um paciente melhorou, ficando sem ronco e dois foram curados, isto é, a respiração alterou-se de oral para nasal e sem ronco. Dos 20 pacientes tratados com placebo, 17 pacientes se mantiveram inalterados, um paciente melhorou do ronco e dois foram curados, não tendo havido diferença estatística significante entre os grupos (P>0,999). CONCLUSÕES: O tratamento homeopático não foi eficaz nas crianças com adenóide obstrutiva, mantendo-se a indicação cirúrgica em 85% dos pacientes. O medicamento homeopático não provocou eventos adversos nas crianças.Instituto Brasileiro de Estudos Homeopáticos Faculdade de Ciências da Saúde de São PauloUniversidade Federal de São Paulo (UNIFESP), Escola Paulista de Medicina (EPM)Universidade Federal de São Paulo (UNIFESP) Escola Paulista de MedicinaUNIFESP, EPMSciEL

Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples

Funder: NCI U24CA211006Abstract: The Cancer Genome Atlas (TCGA) and International Cancer Genome Consortium (ICGC) curated consensus somatic mutation calls using whole exome sequencing (WES) and whole genome sequencing (WGS), respectively. Here, as part of the ICGC/TCGA Pan-Cancer Analysis of Whole Genomes (PCAWG) Consortium, which aggregated whole genome sequencing data from 2,658 cancers across 38 tumour types, we compare WES and WGS side-by-side from 746 TCGA samples, finding that ~80% of mutations overlap in covered exonic regions. We estimate that low variant allele fraction (VAF < 15%) and clonal heterogeneity contribute up to 68% of private WGS mutations and 71% of private WES mutations. We observe that ~30% of private WGS mutations trace to mutations identified by a single variant caller in WES consensus efforts. WGS captures both ~50% more variation in exonic regions and un-observed mutations in loci with variable GC-content. Together, our analysis highlights technological divergences between two reproducible somatic variant detection efforts

Sex differences in oncogenic mutational processes

Funder: Canadian Network for Research and Innovation in Machining Technology, Natural Sciences and Engineering Research Council of Canada (NSERC Canadian Network for Research and Innovation in Machining Technology); doi: https://doi.org/10.13039/501100002790Funder: Genome Canada (Génome Canada); doi: https://doi.org/10.13039/100008762Funder: Canada Foundation for Innovation (Fondation canadienne pour l'innovation); doi: https://doi.org/10.13039/501100000196Funder: Terry Fox Research Institute (Institut de Recherche Terry Fox); doi: https://doi.org/10.13039/501100004376Abstract: Sex differences have been observed in multiple facets of cancer epidemiology, treatment and biology, and in most cancers outside the sex organs. Efforts to link these clinical differences to specific molecular features have focused on somatic mutations within the coding regions of the genome. Here we report a pan-cancer analysis of sex differences in whole genomes of 1983 tumours of 28 subtypes as part of the ICGC/TCGA Pan-Cancer Analysis of Whole Genomes (PCAWG) Consortium. We both confirm the results of exome studies, and also uncover previously undescribed sex differences. These include sex-biases in coding and non-coding cancer drivers, mutation prevalence and strikingly, in mutational signatures related to underlying mutational processes. These results underline the pervasiveness of molecular sex differences and strengthen the call for increased consideration of sex in molecular cancer research

Sex differences in oncogenic mutational processes

Sex differences have been observed in multiple facets of cancer epidemiology, treatment and biology, and in most cancers outside the sex organs. Efforts to link these clinical differences to specific molecular features have focused on somatic mutations within the coding regions of the genome. Here we report a pan-cancer analysis of sex differences in whole genomes of 1983 tumours of 28 subtypes as part of the ICGC/TCGA Pan-Cancer Analysis of Whole Genomes (PCAWG) Consortium. We both confirm the results of exome studies, and also uncover previously undescribed sex differences. These include sex-biases in coding and non-coding cancer drivers, mutation prevalence and strikingly, in mutational signatures related to underlying mutational processes. These results underline the pervasiveness of molecular sex differences and strengthen the call for increased consideration of sex in molecular cancer research.Sex differences have been observed in multiple facets of cancer epidemiology, treatment and biology, and in most cancers outside the sex organs. Efforts to link these clinical differences to specific molecular features have focused on somatic mutations within the coding regions of the genome. Here we report a pan-cancer analysis of sex differences in whole genomes of 1983 tumours of 28 subtypes as part of the ICGC/TCGA Pan-Cancer Analysis of Whole Genomes (PCAWG) Consortium. We both confirm the results of exome studies, and also uncover previously undescribed sex differences. These include sex-biases in coding and non-coding cancer drivers, mutation prevalence and strikingly, in mutational signatures related to underlying mutational processes. These results underline the pervasiveness of molecular sex differences and strengthen the call for increased consideration of sex in molecular cancer research.Peer reviewe

Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples

Funder: NCI U24CA211006Abstract: The Cancer Genome Atlas (TCGA) and International Cancer Genome Consortium (ICGC) curated consensus somatic mutation calls using whole exome sequencing (WES) and whole genome sequencing (WGS), respectively. Here, as part of the ICGC/TCGA Pan-Cancer Analysis of Whole Genomes (PCAWG) Consortium, which aggregated whole genome sequencing data from 2,658 cancers across 38 tumour types, we compare WES and WGS side-by-side from 746 TCGA samples, finding that ~80% of mutations overlap in covered exonic regions. We estimate that low variant allele fraction (VAF < 15%) and clonal heterogeneity contribute up to 68% of private WGS mutations and 71% of private WES mutations. We observe that ~30% of private WGS mutations trace to mutations identified by a single variant caller in WES consensus efforts. WGS captures both ~50% more variation in exonic regions and un-observed mutations in loci with variable GC-content. Together, our analysis highlights technological divergences between two reproducible somatic variant detection efforts

Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples

The Cancer Genome Atlas (TCGA) and International Cancer Genome Consortium (ICGC) curated consensus somatic mutation calls using whole exome sequencing (WES) and whole genome sequencing (WGS), respectively. Here, as part of the ICGC/TCGA Pan-Cancer Analysis of Whole Genomes (PCAWG) Consortium, which aggregated whole genome sequencing data from 2,658 cancers across 38 tumour types, we compare WES and WGS side-by-side from 746 TCGA samples, finding that ~80% of mutations overlap in covered exonic regions. We estimate that low variant allele fraction (VAF < 15%) and clonal heterogeneity contribute up to 68% of private WGS mutations and 71% of private WES mutations. We observe that ~30% of private WGS mutations trace to mutations identified by a single variant caller in WES consensus efforts. WGS captures both ~50% more variation in exonic regions and un-observed mutations in loci with variable GC-content. Together, our analysis highlights technological divergences between two reproducible somatic variant detection efforts.The Cancer Genome Atlas (TCGA) and International Cancer Genome Consortium (ICGC) curated consensus somatic mutation calls using whole exome sequencing (WES) and whole genome sequencing (WGS), respectively. Here, as part of the ICGC/TCGA Pan-Cancer Analysis of Whole Genomes (PCAWG) Consortium, which aggregated whole genome sequencing data from 2,658 cancers across 38 tumour types, we compare WES and WGS side-by-side from 746 TCGA samples, finding that -80% of mutations overlap in covered exonic regions. We estimate that low variant allele fraction (VAFPeer reviewe